There is no denying the consolidation of companies in the pharma/bio industry. From 1996 to 2011 (16 years) there was approximately $776bn in M&A activity, while in the last eight years this amount has been equaled in half the time ($829bn).
It s unquestionable that the dollar value aOriginal Article
